Fields marked with an asterisk are required Your Name * Rules of commenting comment to be published

Company United Therapeutics endocytosis announced May 26 that the FDA has approved its drug Adcirca (tadalafil) for the treatment of pulmonary arterial hypertension. Tadalafil, which is marketed by Eli Lilly & Co. Branded Cialis / Cialis for the treatment of erectile dysfunction, is the first 5 phosphodiesterase inhibitor for the treatment of pulmonary arterial hypertension.
Recall that the agreement on a license agreement on joint marketing in the U.S. market the drug tadalafil for the treatment endocytosis of pulmonary hypertension between the two companies was signed in November 2008 (http://www.apteka.ua/online/27856/).
United Therapeutics acquired rights to market the drug in the United States as a therapeutic agent for the treatment of pulmonary arterial hypertension in the company Eli Lilly & Co. Last year. Commenting on the approval of the FDA, the analyst Terence Flynn (Terence Flynn) of Lazard Capital Markets endocytosis noted that, in his opinion, Adcirca beat shares Revatio (sildenafil, Pfizer ) on the market drugs for the treatment of pulmonary arterial hypertension due to a more convenient endocytosis dosing and relatively low cost. Annual sales Adcirca, according to analysts, may reach its peak in more than 150 million endocytosis dollars. U.S. North American endocytosis States.
Roger Jeffs (Roger Jeffs), Chief Operating Officer United Therapeutics , said the marketing of the drug is scheduled to begin in early August. Shares United Therapeutics therefore increased in price by 12.7%.? endocytosis
Fields marked with an asterisk are required Your Name * Rules of commenting comment to be published after moderation edition of the publication. We reserve the right not to publish posts that are not related to the material and to the discussion topic. Certainly it is prohibited: - profanity. - Comments that defame the reputation of companies, endocytosis organizations, products, insults resource users, authors or participants articles. - Incitement to ethnic, religious or other hatred, incitement to illegal acts; - advertising - posting links to other resources without the consent of a site moderator. E-Mail * Position, Message * Subscribe to new posts Dear colleagues! Filling the example field is required to post comments and is designed to protect Internet resources from spam (junk e-mail messages).
Enter the numbers shown in the image * Other articles in this section endocytosis [22/11/2013 18:25] Gloves Ansell - the protection of medical personnel! [11/22/2013 15:10] endocytosis Why allergic endocytosis colds more often? [21/11/2013 16:30] Milk joy at the origins of longevity [21/11/2013 14:46] Napkins DRY DRY: for all occasions! [21/11/2013 09:47] "Doctor Biocon" cares about women's health [11/15/2013 22:22] PANGROL with exocrine insufficiency endocytosis - a simple answer endocytosis to a complex issue [11/15/2013 14:20] Altai honey for your health! [14/11/2013 13:08] To drink or not to drink: a sense of proportion is welcome [08.11.2013 20:48] How balm for the soul: treat colds rationally [08/11/2013 19:49] Antidepressants and sedatives . Two different paths to spiritual harmony Latest News and Articles [22/11/2013 19:22] List of drugs for which the State Service of Ukraine on drugs issued orders endocytosis banning / permit their implementation 18.11.2013 till 22.11.2013 g . [22/11/2013 18:25] Gloves Ansell - the protection of medical personnel! [11/22/2013 18:11] Farmpromotsiya in Ukraine: Analytical and practical aspects [11.22.2013 17:54] The specialized seminar "Transformation farmpredstavitelstv: new opportunities in the new year" (AND TRANSFORMED FOR å) [2013 - 11-22 16:34] Brief analysis of the pharmaceutical endocytosis market: results endocytosis of the October 2013 [11/22/2013 15:57] od SHEET 22.11.2013 p. 25306-1.3/2.1/17-13 endocytosis [2013-11-22 15:56] Rozporyadzhennya od 22.11.2013 p. 25304-1.3/2.2/17-13 [2013-11-22 15:56] od SHEET 22.11.2013 p. 25303-1.3/2.0/17-13 endocytosis [2013-11-22 15:55] Rozporyadzhennya od 22.11.2013 p. 25297-1.3/2.2/17-13 [2013-11-22 15:55] Rozporyadzhennya od 22.11.2013 p. 25291-1.3/2.1/17-13 Drugs, medicines and drug prices and all news